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Experimental allergic encephalomyefitis  (EAE),  an experimental  model  of 
demyelinating diseases  of  the  central  nervous system, has been intensively 
studied in recent years. Definition of the pathogenic mechanisms  has been 
sought with a wide range of experimental  approaches,  but some of the basic 
questions  are still  unanswered.  The relative role of delayed hypersensitivity 
and classical circulating  antibody in the pathogenesis  of the disease has been 
one of the most controversial  of these questions. This problem is considered in 
several recent reviews of EAE (1-3). 
One means of studying the character of this immunologic disease is to consider 
the ways by which it can be modified or prevented. Treatment with salicylates 
(4), ACTH and cortisone (5-7),  and nitrogen mustard (8, 9) has been shown to 
affect the incidence and severity of EAE. None of these drugs was effective, 
however,  if  treatment  was  started  after  injection  of  the  encephalitogenic 
preparation. Moreover,  none of these experiments  established  that the disease 
was modified by the anti-immunologic  activity of the drugs,  and not by their 
antihematologic,  anti-inflammatory,  or non-specific toxic effects. 
To consider whether or not EAE can be modified by a more specific suppres- 
sion of immunologic processes, the effect of 6-mercaptopurine  (6-MP) has been 
studied. The anti-immunologic  properties  of this drug, developed  as an anti- 
leukemic, were first noted by Schwartz  et al.  (10). Their demonstration that 
6-MP suppresses  the primary antibody response  to bovine serum albumin in 
rabbits stimulated the investigation of the effect of the drug on EAE and later 
studies in which it has been shown that the drug affects the secondary immune 
response  (11), antibody production in highly sensitized  rabbits  (12), homo- 
graft rejection  (13), inflammation (14), and delayed hypersensitivity (15). 
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We have previously reported  that  6-MP prevented EAE  when rabbits  were 
treated  with  the  drug  from  the  day  of  injection  of  the  spinal  cord-adjuvant 
emulsion  (16).  This paper presents  the results  of further  studies  of the effects 
of 6-MP on EAE,  with special emphasis  on the prevention of the disease with 
delayed 6-MP  administration,  and  a  consideration  of the possible  mechanisms 
by which  the drug  may be affecting  the disease. 
Materials and Methods 
Animals.--Animals used in these experiments were albino hybrid  rabbits  of both  sexes, 
weighing from 2 to 3 kg, obtained from a single local breeder, and Hartley strain albino guinea 
pigs of both sexes, weighing between 400 and 550 gm, obtained from a single breeder. These 
animals were kept in the laboratory for at least 2 weeks prior to experimentation to insure a 
disease-free stock acclimated to laboratory conditions. Except in the fasting experiment, they 
were offered laboratory chow and water ad libitum. Rabbits in the fasting study received only 
water. No antibiotic supplements were used. 
6-Mercaptopurine.---6-Mercaptopurine (purinethol),  kindly supplied by Burroughs,  Well- 
come and Co., Inc., Tuckahoe, New York, was dissolved in 1 r¢ NaOH (0.15 gm/ml). Fresh 
preparations were made up every other day and kept under refrigeration. The solution had a 
pH of 10 and was mildly irritating when injected. In rabbits it was administered by intrave- 
nous injection in the marginal ear vein, and in guinea pigs it was administered intraperitone- 
ally or intramuscularly into the deep muscles of the back. 
The dosages of 6-MP used caused moderate toxic mortality in some experiments. Animals 
were considered to have died from the toxic effects of 6-MP if death occurred within the period 
of drug administration or during the 4  following days,  the animals had  shown no signs of 
paralysis, and histologic study of the central nervous system showed no lesions of EAE. 
Encephalitogenic Agent.--Fresh whole  rabbit  spinal  cord  was  freed  from  meninges  and 
large blood vessels by forcing it through a stainless steel tissue press containing a no. 80 mesh 
copper wire screen.  Rabbits were sensitized with an emulsion containing: 20 gm wet weight 
of spinal cord, 10 ml of complete Freund's adjuvant  (Difeo Laboratories, Detroit),  10 ml of 
hayol F  (Esso Standard Oil Company, New York), 2 ml of arlacel A (kindly furnished by the 
Atlas Powder Company, Wilmington), and  500 rag.  of killed, dried, ground Mycobaaerium 
butyricum (Difco). Rabbits received 0.1 ml. of this emulsion intradermally in each hind foot 
pad. 
The  encephalitogenic emulsion for guinea pigs was prepared  with  smaller quantities  of 
nervous tissue and Mycobacterium. In experiments GP-I and  GP-2 it contained: 500 mg of 
fresh rabbit spinal cord in 20 ml of saline,  17 ml of  bayol  F,  3  ml  of  arlacel  A,  and  100  mg 
of the Mycobtwterium. In experiments GP-3 and GP-4 it contained: 1 gm of lyophilized rabbit 
spinal cord, 8.5 ml of bayol F, 1.5 ml of arlaeel A, and  100 mg of Mycobaacriura bulyricum. 
Each guinea pig received 0.1  ml of the emulsion intradermally on the anterior aspect of the 
thorax. 
These encephalitogenic preparations resulted in at least 75 per cent incidence of EAE in 
control rabbits and guinea pigs. 
Obsarvatiort.--Sigus of EAE appear 11 to 18 days after the injection of the spinal cord-adju- 
vant emulsion, and include weakness, weight loss,  paralysis,  loss of sphincter  control, and 
death. Paralysis is the most consistent sign of the disease,  and was the index used in all these 
studies. Animals were observed daily and were considered to have EAE only if definite signs 
of paralysis were observed in either the front or hind quarters. Central nervous system tissue 
of treated and control animals was examined to compare the clinical and histologie signs. L.  W.  HOYER,  R.  A.  GOOD, AND  R.  M.  CONDIE  313 
Histologic study.--Sections of the brain and spinal cord were examined in animals sacrificed 
during the experiments, in all animals that died without prior paralysis, and in about one-third 
of those that died after demonstrating paralytic signs of EAE. At least three sections of each 
of five areas of the central nervous system: lumbar spinal cord, cervical spinal cord, medulla, 
pons, and cerebrum, were examined in each case. The tissue was fixed in formalin and stained 
with hematoxylin and eosin. The pathologic material was evaluated without knowledge of the 
clinical course of the animal. 
Experiment No. 
R-la 
R-lb 
R-lc 
R-2 
R-3 
Summary of R-lc 
R-2, and R-3 
TABLE  I 
flea of Early  Treatment  with 6-MP on EAE in Rabbits 
Treatment  6-MP dosage  period 
mg/kg/day  days* 
6  0 to 18 
9  0 to 18 
12  0 to 18 
12  --2 to 18 
12  0 to 18 
12 
6-MP 
mortality 
o/lo 
0/9 
1/8 
2/9 
3/13 
6/30 
(20%) 
Incidence of paralysh§ 
By day 18 
5-MP-  Controls  treated 
4/tO  } 
3/9  8/9 
0/8 
0/9  6/9 
o/n  8/lO 
0/28  22/28 
(--)  (80%) 
By day 40 
6-MP-  treated  Controls 
8/lO  } 
9/9  9/9 
6/7 
6/7  8/9 
6/7  lO/lO 
18/21:~  27/28 
(86%)  (96%) 
* Day 0  =  day of injection of spinal cord 
Three animals were sacrificed on day  18. 
§ Numerator is cumulative incidence of paralysis (including those few deaths from EAE 
not preceded by observed paralysis, but confirmed histologically); the denominator is the 
number of animals in the experiment less the number of deaths from 6-MP toxicity. 
RESULTS 
Early  Treatment  with 6-MP.--Rabbits  were given  daily intravenous injec- 
tions of 6-MP  in several  dosages,  beginning  on the day of injection of the 
encephalitogenic  preparation and continuing for 18 days. Early studies  indi- 
cated that most rabbits tolerated 18 days of 6-MP treatment fairly well, but 
that signs of severe 6-MP toxicity appeared  when the drug was continued for 
longer periods. 
Table I summarizes the results of a series of experiments using three dosage 
levels of 6-MP. It is apparent that the lower dosages of 6-MP (6 and 9 mg/kg/ 
day)  reduced  the incidence  of paralysis by day  18,  although some  treated 
animals showed clinical signs of EAE. When 6-MP was given in a dosage of 12 
mg/kg/day, however,  it completely prevented paralysis during the period of 
drug administration. Data from experiments  R-lc, R-2  and R-3  are graphed 
in Fig. 1 to demonstrate the latent period which separated the discontinuation 
of 6-MP treatment and the onset of paralysis.  Mter 6 to 20 days these rabbits 314  EXPERIMd~NTAL  ALLERGIC  ENCEPHALOMYELITIS 
developed  paralytic  encephalomyelitis  which  differed  in  no  way  from  the 
disease observed in control animals. 
Histologic study confirmed the clinical observations. 3 animals from experi- 
ment R-3  were sacrificed on day 18,  and autopsies were performed on the 6 
animals  that died of 6-MP  toxicity. All had normal central nervous system 
tissue  and  no histologic  signs  of  EAE.  Nervous  tissue  of  11  rabbits  which 
became paralyzed after discontinuation  of  6-MP  was  also  examined.  These 
sections showed the characteristic perivascu]ar  inflammatory  lesions of  EAE 
(1, 2). 
73 
(D 
N 
m 
CS 
O 
CL 
E 
0J 
O 
(1) 
rl 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
I 
0 
....  I, 
]  I 
4 
I  I  I  1 
8  12 
6-MP 
_2 
=g  days 
I  ]  I  I  I 
32  36 
_1  1  I  I  I  1  I  I 
16  20  24  28 
,I 
days  after  injection  of 
cord  -  Adjuvant  Emulsion 
12  mg/kg/doy 
Time  in 
Spinal 
FIG. 1. The effect of 6-MP on EAE in rabbits. 
Delayed  Treatment  with 6-MP.--To characterize more generally the effects 
of 6-MP, we investigated treatment schedules started after the injection of the 
spinal cord-adjuvant emulsion. Since control rabbits first show paralytic signs 
of EAE after day 12, treatment was initiated 9 and 12 days after administration 
of the encephalitogenic preparation, during what would seem to be the most 
active period of the immunologic reaction. The data of Table II indicate the 
effectiveness of 6-MP in suppressing EAE, despite the delay in treatment. 
A better picture of the relationship between the period of 6-MP treatment 
and suppression of EAE is presented in Figs. 2 and 3 which graph the data of L.  W.  HOYER,  R.  A.  GOOD, AND R.  M.  CONDIE  315 
experiments  R-5  and R-6  (Table II). The dosage level was  18  mg/kg/day, 
administered from day 9  (Fig.  2)  and day 12  (Fig. 3). When treatment was 
started on the 9th day, there were statistically significant  differences in the 
incidence of paralysis in control and 6-MP-treated animals from day 14 to day 
23(p was less than 0.05 when the two groups were compared by the chi-square 
test with the Yates modification).  When 6-MP treatment was delayed until 
the  12th  day (Fig.  3),  the incidence  of paralysis in the treated and control 
TABLE II 
Effect of Ddayed  Treatment  ~ith  6-MP on EAE in  Rabbits 
Experiment No.  6-MP dosage  Treatment 
period 
6-MP 
mortality 
mg/k~day  days* 
R-4  12  9 to 25  5/10 
R-5a  18  9 to 18  1/10 
R-6a  18  9 to 18  3/10 
Summary.  After 
day 9 
18 
18 
R-5b 
R-6b 
12 to 21 
12 to 21 
After 
day 12 
Summary 
1/lO 
1/9 
Incidence of paralysis:[ 
By day 18 
~MP-  ConSols  t~ated 
2/10  8/lO 
I/I0  7/10 
2/8  8/9 
5/28  23/29 
(18%)  (79%) 
4/t0  7/10 
S/9  8/9 
9/19  15/19 
(47%)  (79%) 
By day 40 
~MP-  ~eated  Consols 
3/5  1o/1o 
8/9  7/lO 
7/7  9/9 
18/21  26/29 
(86%)  (90%) 
6/9  7/10 
6/8  9/9 
12/17  16/19 
(71%)  (84%) 
* Day 0  ---- day of injection of spinal cord 
Numerator is cumulative inddence of paralysis  (including those few deaths from EAE 
not preceded by observed paralysis, but confirmed histologically); the denominator is the 
number of animals in the experiment less the number of deaths from 6-MP toxicity. 
groups was about the same until day 14. Very few 6-MP-treated rabbits became 
paralyzed after day 15, however, while there was no change in the rate at which 
control animals became paralyzed. The difference between the control and 6- 
MP-treated groups  was not statistically significant  (p was 0.09 for day 18) 
because so many treated rabbits had become paralyzed by day 15, before drug 
treatment began to have any effect. The break in the curve was most striking, 
however, and a relative plateau after day 15, such as that of Fig. 3, has never 
been observed in control groups in which EAE antigen has been administered 
to over 500 rabbits. 
Once paralytic signs of EAE have developed,  spontaneous remissions  are 
very rare.  Although 6-MP  injections  were  continued in  the animals which 316  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
became paralyzed from days 12 to 15  (Fig. 3), remissions were not observed. 
Thus, 6-MP prevented EAE in many animals  even when its administration 
was delayed for 12 days, but had no effect when paralysis was imminent or 
already present. 
The Latent  Period  after Discontinuation  of 6-MP  Treatment.--In  all of the 
experiments  in  which  EAE  was  prevented,  the  animals  remained  well  for 
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FIG. 2. The effect of 6-MP on EAE in rabbits when treatment started on day 9. 
several days after discontinuation of 6-MP, but developed paralytic signs  of 
the  disease  after a  latent period.  To compare the development of paralysis 
in different groups of animals, we determined the time interval before 40 per 
cent of the rabbits became paralyzed in each experiment. This arbitrary value, 
equal to one-half the total incidence of paralysis in most experiments, proved 
to be a  highly reproducible measure for the several control groups as well as 
for separate treated groups with the same protocol. 
As Figs.  1 and 4 indicate, 40 per cent of control rabbits were paralyzed by 
the 14th day after spinal cord-adjuvant injection, while 40 per cent of the 6- 
MP-treated animals became paralyzed 9 days after the drug was discontinued, L.  W.  HOYER,  R.  A.  GOOD~  AND  ~R.  M'.  CONDrI~.  317 
whether it had been given for 9 days (Fig. 4) or 18 days (Fig. 1). Four other 
treatment schedules were also investigated (Table III) and each was followed 
by a latent period of either 9 or 10 days, regardless of the duration of 6-MP 
treatment. The group given 6-MP for 5 days is a good example. Paralysis was 
not delayed for 5 days, but developed at the same rate as in the control animals, 
so that 40 per cent of the animals were paralyzed by the 14th day (9 days after 
6-MP was discontinued). 
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The Effect of 6-MP on EAE in Guinea Pigs.--Field's  (17) report that 6-MP 
did not prevent EKE in the guinea pig suggested that the effect of 6-MP on 
EKE might only obtain in rabbits. Our own studies, however, summarized in 
Table IV, showed suppression of EAE by 6-MP in the guinea pig as well, but 
we found that dosage and route of administration were  more  critical  in  this 
species than in the rabbit. 
When the drug was given to guinea pigs by the intraperitoneal route, a large 
dosage was required to obtain an effect. As shown in Table IV, the onset of 
paralysis was delayed considerably in guinea pigs given 150 mg/kg/day intra- 318  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
peritoneally for 12 days. The drug was more effective, however, when adminis- 
tered into the deep muscles of the back. Nine daily injections of 50 mg/kg/day 
by this route prevented the development of EAE, with little increase in 6-MP 
mortality. 
As in the case of the rabbit, delayed treatment with 6-MP was effective in 
preventing  the  disease.  Treatment  started 5  days after the  injection of the 
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spinal cord-adjuvant emulsion prevented paralytic signs of EAE, but when 
6-MP was not given until the 7th day, it had little effect on the disease (Table 
IV). 
Hence, although larger and more toxic dosages of 6-MP are required in the 
guinea pig than in the rabbit,  the drug effectively suppresses  EAE in both 
species.  This is in contrast with x-irradiation, which does not delay or suppress 
EAE in the guinea pig, but is effective in the rabbit (18,  19). 
The Effect of 6-MP on Leukocytes.--To consider the possibility that the effect 
of 6-MP on EAE was due to leukopenia or neutropenia, total and differential L.  W.  HOYER,  R.  A.  GOOD~  AND  R.  M.  CONDIE  319 
leukocyte counts were determined on animals in several experiments: R-2 and 
R-3  (Table I), and R-6a and b  (Table II). 6-MP did not produce a  profound 
leukopenia in any of  these  experiments.  Fig. 5  illustrates the findings in  the 
TABLE III 
Development of EAE after Discontinuation  of 6-MP Treatment in Rabbits 
Number of rabbits 
4S§ 
8 
9 
8 
8 
9 
21 
6-MP dosage 
mg/kg/da~ 
12 
12 
12 
18 
12 
12 
Last day of 6-MP 
treatment* 
3 
5 
7 
9 
13 
18 
[ 
i  Day 40 per cent of 
animals psralyzed~ 
14§ 
13 
14 
17 
18 
23 
27 
Interval between las! 
day of treatment to 
day of 40 ~er cent 
inciaence 
10 
9 
10 
9 
10 
9 
* 6-MP was started on the day of administration of the spinal cord-adjuvant preparation 
in all but the 48 control animals (given the EAE antigen only). 
~: The day of 40 per cent incidence of paralysis in each group was approximated (to the 
nearest day) from a  graph of the cumulative incidence  of paralysis as a function of time, 
as illustrated in Figs. 1 and 4. 
§ The control summary is composed of 5 groups of 9 or 10 rabbits each. 40 per cent paralysis 
was noted by day 13 in one group, day 14 in 3 groups,  and day 15 in one group. 
Experiment 
No. 
GP-1 
GP-2 
GP-3 
GP-4 
TABLE IV 
[ect of Early and Ddayed  Trealmen~ with 6-MP on EAE in Guinea Pigs 
6-MP 
dosage 
Treatment 
period 
days* 
0 to 12 
0 to 9 
5 to 14 
7 to 16 
6-~ 
mortaliW 
12/25 
17/30 
8/10 
1/10 
ms/kS/day 
150, ip 
5O, im 
5O, im 
50, 
Incidence of paralysis 
By day 14  By day 28 
6-MP- 
treated  Controls 
3/13  9/10 
o/13  10/17 
o/8  7/8 
4/9  7/8 
6-MP- 
treated  Controls 
9/13  10/lO 
4113  13/17 
417  718 
7/9  7/8 
* Day 0  ffi day of injection of spinal cord emulsion 
animals of experiment R-3, treated with  12 mg/kg/day  of 6-MP for  18 days, 
and is representative of the data from the other groups. The total number of 
leukocytes and granulocytes rose in the control rabbits while the lymphocyte 
level remained relatively constant. In the 6-MP-treated animals, the average 
total white count fell slightly (10  to 30 per cent, but never below 7000  cells/ 320  EXPERIMENTAL  ALLERGIC ENCEPHALOMYELITIS 
ram3), as did the granulocytes (10 to 50 per cent, but never below 2000 cell# 
mm3), but the number of lymphocytes (3000 to 6000 cells/mm  8) again remained 
relatively constant. 
The 20 per cent toxic mortality might be considered evidence of leukopenia; 
however, only 2 of 10 rabbits dying of 6-MP toxicity during hematologic study 
had  decreased  granulocytes or  lymphocytes when  last  tested  before  death. 
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FIG. 5. The effect  of 6-MP on leukocytes  in rabbits stimulated with a spinal cord-adjuvant 
emulsion. 
Autopsy of animals dying from 6-MP toxicity often revealed gastrointestinal 
obstruction and ulceration, and peritonitis: findings consistent with reports of a 
relatively high concentration of 6-MP  in  the rapidly proliferating epithelial 
tissue of the gastrointestinal tract (20) and a high incidence of gastrointestinal 
lesions after 6-MP treatment (21). 
Non-specific  Toxicity  and  Debilitation.--Because  the  most  effective 6-MP 
dosage was quite high (12 mg/kg/day in rabbits)  and resulted in 20 per cent 
mortality, one might consider the suppression of EAE a reflection of toxicity 
and debilitation rather than specific effects of 6-MP on immunologic processes. 
The majority of the animals did not show signs of debilitation, however, and L. W. HOYER,  R. A. GOOD, AND  R. M. CONDIE  321 
were healthy enough to manifest the disease after the drug was discontinued. 
Moreover, when lower dosages of 6-MP were used (6 and 9 mg/kg/day, Table 
I), there was a delay in development of EAE in the absence of any toxic signs. 
The data in Tables V and VI emphasize the lack of correlation of signs of 
toxicity and  suppression of EAE.  Rabbits  were pretreated with 6  mg/kg of 
6-MP for 12 days, with completion of the course 2 days before administration 
TABLE V 
Effect  of Pregreatment with  6-MP  on  EAE  in  RabMts 
Treatment  6-MP Mortality 
6-MP, 6 mg/kg/day, Days --13 to --2* ........  2/10 
Control rabbits, not given 6-MP  ............... 
* Day 0 --- day of injection of spinal cord-ad nvant emulsion 
Incidence of Paralysis 
By day 16  By day 40 
s/8  8/8 
3/9  9/9 
TABLE VI 
Comparative Effeas of 6-MP  Tre,  atment  and Fasting on Weight and Incidence  of EAE 
Number of 
Treatment*  Animals 
None 
6-MP,  12  mg/kg/day, 
Days 0 to 18 (8 rab- 
bits),  Days --2 to 18 
(9  rabbits)... 
Fasting, days 0-15. 
19 
17 
I0 
Mean  weight on 
Day 0 
kg 
2.60 
2.63  2.27 
2.40  1.61 
Weight loss over 
the 15 days 
No. of 
rabbits 
paralyzed 
on day 15  Day 15 
kg 
2.29 
kg  per ce~t 
0.31  12 
0.36  14 
0.79  33 
12/19 
o/17 
5/lo 
Effect of treatmenl 
on EAE 
Complete  sup, 
pression 
None 
of the encephalitogenic emulsion (Table V). While this dosage did not cause 
any toxic mortality in rabbits which had previously received the encephalito- 
genic  emulsion  (Experiment R-la,  Table  I),  this  schedule  caused  moderate 
weight loss and 20 per cent toxic mortality in  these unsensitized rabbits.  In 
spite of the evident toxic effects of 6-MP in the rabbits pretreated with 6-MP, 
the subsequent development of EAE was not delayed. Rather,  these animals 
showed paralytic signs somewhat earlier than the control animals. 
The weight loss in 6-MP-treated rabbits in experiments R-lc and R-2 was 
no greater than in control animals  developing EAE  (Table VI).  To consider 
more directly the factors of weight loss and debility, a  group of rabbits was 
* All animals received 0.1 ml of spinal cord-ad uvant in each hind  foot pad on day 0. 322  EXPERIMENTAL  ALLERGIC  ENCEPHALOMYELITIS 
fasted for 15 days after administering of the encephalitogenic emulsion. Fasting 
produced much greater weight loss (Table VI) and more evident debility than 
6-MP  treatment, but did not prevent the development of paralytic signs of 
EAE. 
DISCUSSION 
Before concluding that 6-MP suppressed EAE by affecting a  basic part of 
the immunologic response to the nervous tissue antigen, we have to consider a 
number of other possible mechanisms. We believe that the evidence indicates 
that 6-MP did not merely mask clinical signs of the disease, and that its effects 
were not the result of leukopenia, non-specific toxicity or debilitation, or anti- 
inflammatory activity. 
The  histologic studies,  the  eventual  development of  EAE  in  the  6-MP- 
treated animals, and the length of the latent period all suggest that 6-MP did 
not merely mask clinical signs of the disease. Histologic study of central nervous 
system tissue from animals sacrificed or dying during the period of drug ad- 
ministration revealed no lesions of EAE.  After 6-MP  was  discontinued,  the 
treated rabbits became paralyzed. In this way, each animal served as its own 
control,  and  showed  that  an  adequate  encephalitogenic stimulus  had  been 
injected.  None  of  the  treated  animals became paralyzed until 6  days after 
6-MP treatment was discontinued, however. Since 6-MP activity is virtually 
absent 24 hours after injection (20),  the length of the latent period also argues 
against the masking effect. 
6-MP's suppression of EAE cannot be ascribed to leukopenia, neutropenia, 
or non-specific toxicity and debilitation. Although 6-MP prevented the usual 
granulocytic response to the spinal cord-adjuvant emulsion, it did not produce 
either severe leukopenia or neutropenia. The 6-MP-treated rabbits lost no more 
weight than the control animals given only the encephalitogenic antigen, yet 
the  disease was  completely suppressed.  In  contrast,  fasting caused  marked 
weight loss and severe debilitation, but did not prevent the disease. 
Finally, 6-MP might have prevented EAE by its antMnflammatory effect. 
This seems unlikely, however, for at least 6 days of pretreatment were necessary 
for 6-MP  to have even a  moderate anti-inflammatory effect in rabbits,  and 
marked suppression of inflammation developed only after 8 days of pretreat- 
ment  (14).  In  contrast,  6-MP  suppressed  EAE  3  days after treatment was 
started. While 6-MP-treated animals did not become paralyzed until the drug 
had been  stopped for 6  days, normal inflammatory cycles were observed  in 
rabbits 2 days after discontinuation of 6-MP administration (14). If the preven- 
tion of EAE were a result of 6-MP's anti-inflammatory properties, one would 
have expected an earlier onset of paralysis after discontinuation of treatment. 
How, then, does the drug affect EAE? It seems to us to be interfering with a 
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sion  and  suppressing  the  development  of  immunologically competent  cells 
and/or antibody formation. 6-MP  has been  shown to interfere with cellular 
metabolism in several ways (22).  Especially suggestive is  the demonstration 
that the drug limits nucleic acid biosynthesis by inhibiting the essential conver- 
sion of inosine ribonucleotide to adenine ribonucleotide (23).  The synthesis of 
adenine-containing coenzymes is also inhibited by 6-MP  (24,  25).  By one or 
more of these several metabolic effects, 6-MP modifies immunologic activity. 
Our findings emphasize that 6-MP's effectiveness must be considered in the 
light of the species,  the route of injection, the dosage, the duration of treat- 
ment, and the relationship of the treatment period to antigenic stimulation. 
Moreover, one must specify the nature and intensity of the stimulation. The 
effect of each of these variables has been illustrated in these experiments. 
The  dosage  of 6-MP  used  is  of great importance,  and  a  relatively small 
increase, as from 9 to 12 mg/kg/day, was associated with striking enhancement 
of effect. Negative reports on the effects of 6-MP (17, 26) may reflect inadequate 
dosage rather  than ineffectiveness of the drug. Toxicity is  a  limiting factor, 
with reference to both dosage and duration, but it was our experience that the 
drug's anti-immunologic properties  were more sensitive to  dosage than were 
the toxic effects. 
These  studies  showed very  clearly  that  6-MP's  effectiveness depends  on 
continued administration. Very short  courses  of treatment had  little effect, 
and rabbits developed EAE at the same rate as controls if given 6-MP for less 
than 6 days. Pretreatment alone, with no 6-MP  after injection of the spinal 
cord, was also ineffective. It is apparent that 6-MP must be given in a manner 
quite different from that used for cytotoxic drugs (e.g. nitrogen mustard) and 
x-irradiation.  Only when  the  antigen  is  essentially eliminated,  as  following 
primary stimulation with a  simple protein antigen (10),  can 6-MP be discon- 
tinued without subsequent evidence of immunologic activity. If the antigen 
persists in the stimulated animals, as it does when the encephalitogenic antigen 
is given in Freund's adjuvant, a  return of immunologic function follows the 
discontinuation of drug treatment (13). 
One of the most debated aspects of EAE concerns the nature of the hyper- 
sensitivity involved in its pathogenesis. Both circulating antibody and delayed 
hypersensitivity have been suggested as essential, but at present neither has 
experimental support which is not subject to alternative interpretation. It was 
hoped that these studies with 6-MP might contribute to the understanding of 
this problem. 
The initial immunologic studies with the drug established its effect on anti- 
body production following primary stimulation (10),  and subsequent experi- 
ments  have  shown  that  the  drug  suppresses  antibody production following 
secondary stimulation (11)  and in highly stimulated animals producing large 
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prevents  delayed hypersensitivity after  BCG  infection in  both  rabbits  and 
guinea pigs  (15),  so  there  does  not seem  to  be  any fundamental difference 
between this phenomenon and antibody production in response to early 6-MP 
treatment. 
Delayed hypersensitivity and antibody production differ in  their response 
to delayed treatment with 6-MP, however. Antibody production in the rabbit 
is very sensitive to delayed treatment with 6-MP, both in the primary immune 
response (10)  and in repeatedly stimulated animals (12).  In contrast, delayed 
treatment  does  not  affect  tuberculin  hypersensitivity in  rabbits.  Although 
6-MP completely prevented delayed sensitivity if treatment was started on the 
same day as BCG infection, large doses of the drug had no effect when initial 
treatment was  delayed for as little as 5  days (15).  6-MP  treatment can be 
delayed for 9 or 12 days, however, and still suppress EAE. Although indirect, 
this is further evidence for the hypothesis that circulating antibody is essential 
in the pathogenesis of EAE in the rabbit. 
The temporal relationships of 6-MP treatment and onset of disease in these 
studies  suggest  that  two  phases  of  activity separate  administration  of  the 
encephalitogenic  emulsion  and  the  appearance  of  paralytic  signs  of  EAE. 
Rabbits normally develop paralysis (40 per cent incidence) in  14 days, while 
6-MP-treated animals become paralyzed (40 per cent incidence) 9 or 10 days 
after discontinuance of treatment. Although the activity of the other 4  or 5 
days is essential in the pathogenesis of EAE, it is not affected by the 6-MP 
treatment. This period may be non-immunologic, perhaps a period of accumula- 
tion of antigen in the popliteal nodes after the emulsion has been injected in 
the hind foot pads. Alternatively, the 4 or 5 day difference may indicate that 
the early stages of the immunologic response to the EAE antigen are less sensi- 
tive to 6-MP than late "productive" stages. 
The prevention of an experimental autoimmune disease, EAE, with 6-MP, 
may have clinical implications. Dameshek and Schwartz have used 6-MP in 
treating patients with some human "autoimmune" diseases (acquired hemolytic 
anemia, lupus erythematosus, and lupoid hepatitis)  and they have reported 
good results (27).  Page (14,28)  subsequently treated three young women with 
plasma cell hepatitis, and in each case 6-MP treatment was followed by remis- 
sion of the liver disease (14,28). 
Drug-induced  remissions  in  human  autoimmune  diseases  are  not  easily 
understood if it is considered essential that 6-MP  treatment accompany the 
initial antigenic stimulation. As  Schwartz has suggested, the effectiveness of 
delayed treatment in preventing EAE  and suppressing  antibody production 
may be analogous to the drug's effect in the human diseases (29). An alternative 
explanation has been offered by Page, who attributes the remissions in cases of 
plasma cell hepatitis to the anti-inflammatory properties of 6-MP (14). 
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sis as a number of human neurologic diseases, including the acute encephalitides 
which follow vaccination and the exanthems of childhood (30, 31). These de- 
velop so quickly that considerable neurologic disturbance is invariably present 
when treatment is initiated and it seems unlikely, as with EAE,  that 6-MP 
could reverse the changes which have already occurred. 
In  subacute  and  chronic  neurologic  diseases,  however,  the  immunologic 
component of pathogenesis--if there is one--might be more amenable to 6-MP 
treatment. Some neuropathologists consider EAE a useful model for multiple 
sclerosis  (30-34)  and feel  that allergy is  very important in  that disease.  If 
continuing immunologic activity is necessary in the development of this demye- 
linating disease, 6-MP offers possible treatment. It seems reasonable to consider 
experimental use of 6-MP in patients with multiple sclerosis,  since there is as 
yet no satisfactory treatment. 
SUMMARY 
I. 6-Mcrcaptopurine (6-MP) prevents experimental allergic  encephalomye- 
litis  (EAE) during  the  period  of  drug  administration  in  both  rabbits  and  guinea 
pigs.  The disease  is  suppressed even  when treatment  is  started  as  late  as the  5th 
day after  antigenic  stimulation  in  guinea  pigs  and the 12th day in  rabbits. 
2. After discontinuation  of 6-MP treatment, there  is  a latent  period before 
the disease  is noted.  The length of this  latent  period is not modified by the 
duration of  6-MP treatment. 
3. The effect  of 6-MP on EAE  is not the result  of leukopcnia,  non-specific 
toxicity and  debilitation,  anti-inflammatory  activity,  or mere  masking  of 
clinical  signs  of the disease.  It is, rather,  the result  of 6-MP's specific  anti- 
immunologic activity. 
4. The effects  of 6-MP  on antibody production, delayed hypersensitivity, 
and EAE  are compared. This provides indirect  evidence for  the importance of 
circulating  antibody  in  the  pathogencsis of  EAE. 
5. The important considerations  in the use of 6-MP are discussed  and the 
possible  usefulness  of  6-MP in  human neurologic  diseases  is  considered. 
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